



Contacts:

David Waldman or Justyna Gudaszewska
Crescendo Communications Europe Sp. z.o.o
Email: mmd@crescendo-ir.com
Tel: (+48 71) 79 11 551

Milestone Medical Inc. Provides First Quarter 2015 Business Update

Reports Continued Progress on U.S. FDA Marketing Clearance; Commencement of Epidural Instrument Clinical Trials; Distribution Agreement in Poland

LIVINGSTON, NJ, May 28, 2015 -- Milestone Medical Inc. (WAR: MMD), today provided a business update for the first quarter ended March 31, 2015.

Leonard Osser, Chief Executive Officer of Milestone Medical, stated, "Our focus in 2015 has been commercializing the epidural and intra-articular ("IA") instruments. We have been in active discussions with distributors in a number of countries in Europe. In March we signed our first exclusive European distribution agreement for the epidural instrument in Poland with TRIMED Sp.z.o.o., one of the largest distributors of diagnostic equipment in Poland. We look forward to announcing similar agreements in other European markets this year. At the same time, we are introducing the epidural instrument to key opinion leaders in Poland and other target European markets to help demonstrate and publicize the efficacy of the instrument. Upon completion of these pilot programs and the additional validation that we anticipate will come from the U.S. clinical trials, we expect to commence full scale commercialization of the epidural instrument."

Mr. Osser continued, "Multi-site clinical trials of our epidural instrument are underway in the U.S. and we look forward to the conclusion of these trials later this year, which we expect will be a catalyst for full commercial launch with both our international and U.S. distribution partners. In the short time since our FDA registration approval to commence with the clinical trials, over 100 clinical trial participants have completed the clinical trial procedures and the estimate is that 400 clinical trial participants will be in the study. We will keep investors informed as we reach benchmarks in terms of new enrollees. Upon successful completion of the clinical trials and statistical analysis of the studies, we will return to the FDA for final marketing clearance. The U.S. epidural market is estimated at over \$7 billion annually and over 2.4 million women in the U.S. receive epidurals while in labor each year with another 1.6 million women who give birth choosing not to have an epidural, mainly due to safety concerns. In Europe, the addressable market for epidurals is estimated to be even larger than the U.S. We continue to advance the intra-articular instrument as well; however it is difficult to accurately predict the exact timing as the U.S. regulatory process is outside of our control."

"We remain focused on uplisting from the NewConnect Market to the Main Market of the Warsaw Stock Exchange. We believe transitioning to the Main Market will help increase awareness and expand the number of potential investors in the company. At the same time, Milestone Medical is applying for a variety of grants in Europe, which would help us to expand both our production as well as our R&D capabilities in Europe."

Mr. Osser concluded, "Milestone Medical is in the development stage, which entails ongoing expenditures for regulatory approval and marketing of our medical instruments. However, we continue to carefully manage our expenses. In addition to the capital we have raised, Milestone Scientific has extended a \$2 million line of credit, which provides us additional working capital to execute our business model and further reinforces Milestone Scientific's confidence in our strategy."

Conference Call

Milestone Medical's executive management team will host a conference call at 2:30 p.m. Central European Time (8:30 a.m. Eastern Time), on Thursday, May 28, 2015. The conference call can be accessed via a live Internet webcast on the Company's website at www.medicalmilestone.com. A webcast replay of the conference call will be accessible on the Company's website at www.medicalmilestone.com for 90 days.

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval for both instruments in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.